Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas

Over recent decades, significant advancements have been made in the treatment and imaging of gliomas. Conventional imaging techniques, such as MRI and CT, play critical roles in glioma diagnosis and treatment but often fail to distinguish between tumor pseudoprogression (Psp) and radiation necrosis...

Full description

Saved in:
Bibliographic Details
Main Authors: Sohil Reddy, Tyler Lung, Shashank Muniyappa, Christine Hadley, Benjamin Templeton, Joel Fritz, Daniel Boulter, Keshav Shah, Raj Singh, Simeng Zhu, Jennifer K. Matsui, Joshua D. Palmer
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/7/1778
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849239770216005632
author Sohil Reddy
Tyler Lung
Shashank Muniyappa
Christine Hadley
Benjamin Templeton
Joel Fritz
Daniel Boulter
Keshav Shah
Raj Singh
Simeng Zhu
Jennifer K. Matsui
Joshua D. Palmer
author_facet Sohil Reddy
Tyler Lung
Shashank Muniyappa
Christine Hadley
Benjamin Templeton
Joel Fritz
Daniel Boulter
Keshav Shah
Raj Singh
Simeng Zhu
Jennifer K. Matsui
Joshua D. Palmer
author_sort Sohil Reddy
collection DOAJ
description Over recent decades, significant advancements have been made in the treatment and imaging of gliomas. Conventional imaging techniques, such as MRI and CT, play critical roles in glioma diagnosis and treatment but often fail to distinguish between tumor pseudoprogression (Psp) and radiation necrosis (RN) versus true progression (TP). Emerging fields like radiomics and radiogenomics are addressing these challenges by extracting quantitative features from medical images and correlating them with genomic data, respectively. This article will discuss several studies that show how radiomic features (RFs) can aid in better patient stratification and prognosis. Radiogenomics, particularly in predicting biomarkers such as <i>MGMT</i> promoter methylation and <i>1p/19q</i> codeletion, shows potential in non-invasive diagnostics. Radiomics also offers tools for predicting tumor recurrence (rBT), essential for treatment management. Further research is needed to standardize these methods and integrate them into clinical practice. This review underscores radiomics and radiogenomics’ potential to revolutionize glioma management, marking a significant shift towards precision neuro-oncology.
format Article
id doaj-art-e35e986e978b4511922e2438c5831381
institution Kabale University
issn 2227-9059
language English
publishDate 2025-07-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-e35e986e978b4511922e2438c58313812025-08-20T04:00:50ZengMDPI AGBiomedicines2227-90592025-07-01137177810.3390/biomedicines13071778Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in GliomasSohil Reddy0Tyler Lung1Shashank Muniyappa2Christine Hadley3Benjamin Templeton4Joel Fritz5Daniel Boulter6Keshav Shah7Raj Singh8Simeng Zhu9Jennifer K. Matsui10Joshua D. Palmer11College of Medicine, The Ohio State University, Columbus, OH 43210, USACollege of Medicine, The Ohio State University, Columbus, OH 43210, USACollege of Medicine, The Ohio State University, Columbus, OH 43210, USACollege of Medicine, The Ohio State University, Columbus, OH 43210, USACollege of Medicine, The Ohio State University, Columbus, OH 43210, USADepartment of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USACollege of Public Health, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Radiation Oncology, Stanford Medicine, Stanford, CA 94305, USADepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USAOver recent decades, significant advancements have been made in the treatment and imaging of gliomas. Conventional imaging techniques, such as MRI and CT, play critical roles in glioma diagnosis and treatment but often fail to distinguish between tumor pseudoprogression (Psp) and radiation necrosis (RN) versus true progression (TP). Emerging fields like radiomics and radiogenomics are addressing these challenges by extracting quantitative features from medical images and correlating them with genomic data, respectively. This article will discuss several studies that show how radiomic features (RFs) can aid in better patient stratification and prognosis. Radiogenomics, particularly in predicting biomarkers such as <i>MGMT</i> promoter methylation and <i>1p/19q</i> codeletion, shows potential in non-invasive diagnostics. Radiomics also offers tools for predicting tumor recurrence (rBT), essential for treatment management. Further research is needed to standardize these methods and integrate them into clinical practice. This review underscores radiomics and radiogenomics’ potential to revolutionize glioma management, marking a significant shift towards precision neuro-oncology.https://www.mdpi.com/2227-9059/13/7/1778gliomaglioblastomaradiomicsradiogenomicspseudoprogressionradiation necrosis
spellingShingle Sohil Reddy
Tyler Lung
Shashank Muniyappa
Christine Hadley
Benjamin Templeton
Joel Fritz
Daniel Boulter
Keshav Shah
Raj Singh
Simeng Zhu
Jennifer K. Matsui
Joshua D. Palmer
Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
Biomedicines
glioma
glioblastoma
radiomics
radiogenomics
pseudoprogression
radiation necrosis
title Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
title_full Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
title_fullStr Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
title_full_unstemmed Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
title_short Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
title_sort radiomics and radiogenomics in differentiating progression pseudoprogression and radiation necrosis in gliomas
topic glioma
glioblastoma
radiomics
radiogenomics
pseudoprogression
radiation necrosis
url https://www.mdpi.com/2227-9059/13/7/1778
work_keys_str_mv AT sohilreddy radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT tylerlung radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT shashankmuniyappa radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT christinehadley radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT benjamintempleton radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT joelfritz radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT danielboulter radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT keshavshah radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT rajsingh radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT simengzhu radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT jenniferkmatsui radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas
AT joshuadpalmer radiomicsandradiogenomicsindifferentiatingprogressionpseudoprogressionandradiationnecrosisingliomas